跳至主要内容
临床试验/IRCT20220111053692N9
IRCT20220111053692N9已完成Unknown

Bioequivalence study of Gliclazide 30 mg Extended Release Tablet (Darou Darman Ariya Sepahan) versus Diamicron MR (SERVIER) Tablet after single oral dosing in healthy volunteers

Aria Sepahan Pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
Male

入选标准

  • 18 to 55 years old
  • Weight in range of 10 % proper body weight
  • All volunteers should be in a good health condition on the basis of medical history ,physical examination , routine blood test.
  • and Possessing negative test for hepatitis B surface antigen (HBs-Ag), Antihepatitis-C antibody (anti-HCV) and anti-HIV.

排除标准

  • Volunteers with hypersensitivity to Gliclazide were excluded.
  • Those with known history of drug abuse. alcohol consumer or cigarette smokers.
  • Taking medications that have drug interactions with gliclazide until one month before studying.
  • disinclination to take the test
  • Blood donation or blood loss of more than 200 ml in the past month

研究者

发起方
Aria Sepahan Pharmaceutical Co

相似试验